Abstrakt
Atrial fibrillation (AF) is the most common sustained arrhythmia. It affects cca 2% of the general population and the prevalence is increasing with age up to 10% among people over 70 years.
One of the most important risks associated with AF is the risk of a cardioembolic event. According to the current ESC guidelines, risk stratification should be done for all AF patients using the CHA2DS2VASc score.
This scoring system is especially useful for low-risk patients. CHA2DS2VASc score can depict patients with very low cardioembolic risk: patients with a CHA2DS2VASc = 0 (or 1 in females) have a very low risk of stroke/thromboembolism, and should not be treated by oral anticoagulation (OAC).
The uncertainities about OAC indication in patients with CHA2DS2VASc = 1 (or possibly in females = 2) were described in a recent position paper, with recommendation to consider new OAC in these patients